What is the recommended protocol for switching from Lexapro (escitalopram) to Viibryd (vilazodone)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: July 8, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

The recommended protocol for switching from Lexapro (escitalopram) to Viibryd (vilazodone) involves a cross-taper approach, starting with a reduction of Lexapro by 50% while initiating Viibryd at a low dose, to minimize the risk of serotonin syndrome and withdrawal symptoms, as suggested by the cautious approach to combining serotonergic drugs 1. When switching from Lexapro to Viibryd, it's crucial to consider the potential for drug interactions and the risk of serotonin syndrome, especially when combining serotonergic drugs 1.

  • Begin by reducing your Lexapro dose by 50% to minimize withdrawal symptoms.
  • Start Viibryd at a low dose, 10 mg daily, for 7 days to allow your body to adjust to the new medication.
  • Then, further reduce Lexapro to 5 mg (or by half again if on a different dose) while increasing Viibryd to 20 mg daily for 7 days.
  • Finally, discontinue Lexapro completely while increasing Viibryd to the target dose of 40 mg daily. This gradual transition is essential to maintain stable serotonin levels in the brain and avoid both withdrawal symptoms and serotonin syndrome, as cautioned against in the management of serotonergic medications 1. Key considerations during this transition include:
  • Taking Viibryd with food to improve absorption and reduce gastrointestinal side effects.
  • Monitoring for temporary side effects such as dizziness, headache, nausea, or sleep disturbances.
  • Consulting your healthcare provider to customize this approach based on your specific medical history and response to medication, given the importance of medical education, training, and experience in safely prescribing antidepressant medications 1.

From the Research

Switching from Lexapro to Viibryd

To switch from Lexapro (escitalopram) to Viibryd (vilazodone), the following steps can be considered:

  • Gradually taper the dose of Lexapro to minimize the risk of withdrawal symptoms and serotonin syndrome 2
  • After tapering Lexapro, an adequate washout period may be necessary before starting Viibryd, although the exact duration is not specified in the available studies
  • Viibryd should be started at a low dose and gradually increased to the recommended dose of 40 mg daily, taken with food to optimize bioavailability 3, 4
  • It is essential to monitor the patient closely during the switching process to minimize the risk of adverse events and ensure a smooth transition

Considerations for Switching

When switching from Lexapro to Viibryd, the following considerations should be taken into account:

  • Vilazodone has a narrow therapeutic dosing range, and the upper boundary is close to that producing intolerable gastrointestinal and central nervous system adverse events 3
  • The patient's age, gender, and renal or hepatic impairment do not require dose adjustments for vilazodone 4
  • Vilazodone should be taken with food to ensure adequate plasma concentrations, and the dose may need to be reduced to 20 mg when taken with strong cytochrome P450 (CYP) 3A4 inhibitors 4

Adverse Events and Interactions

The adverse event profile of vilazodone is similar to that of selective serotonin reuptake inhibitors, and common adverse events include diarrhea, nausea, and headache 5

  • The risk of sexual dysfunction is reported to be low with vilazodone 6, 5
  • It is essential to monitor the patient for potential drug-drug interactions, particularly when co-administering vilazodone with other antidepressants or strong CYP3A4 inhibitors 2, 4

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Switching and stopping antidepressants.

Australian prescriber, 2016

Research

Vilazodone hydrochloride, a combined SSRI and 5-HT1A receptor agonist for major depressive disorder.

The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists, 2012

Research

Vilazodone (Viibryd)--a new antidepressant.

The Medical letter on drugs and therapeutics, 2011

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.